Literature DB >> 28451993

Key rates for the grades and transformation ability of glioma: model simulations and clinical cases.

Elizabeth Scribner1,2, James R Hackney3, Hannah C Machemehl1, Reina Afiouni1, Krishna R Patel1, Hassan M Fathallah-Shaykh4,5,6.   

Abstract

Tumor progression to higher grade is a fundamental property of cancer. The malignant advancement of the pathological features may either develop during the later stages of cancer growth (natural evolution) or it may necessitate new mutations or molecular events that alter the rates of growth, dispersion, or neovascularization (transformation). Here, we model the pathological and radiological features of grades 2-4 gliomas at the times of diagnosis and death and study grade development and the progression to higher grades. We perform a retrospective review of clinical cases based on model predictions. Simulations uncover two unusual patterns of glioma progression, which are supported by clinical cases: (1) some grades 2 and 3 gliomas lack the ability of progression to higher grades, and (2) grade 3 glioma may evolve to GBM in a few weeks. All 13 gliomas that recurred at the same grade carry either the IDH1-R132H or the ATRX mutation. All (five of five) grade 3 tumors are 1p/19q co-deleted, IDH1-R132H mutated and ATRX wt. Furthermore, three of seven grade 2 gliomas are both IDH1-R132H mutated and ATRX mutated. Simulations replicate the good prognosis of secondary GBM. The results support the hypothesis that constant rates of dispersion, proliferation, and angiogenesis prescribe either a natural evolution or the inability to progress to higher grades. Furthermore, the accrual of molecular events that change a tumor's ability to infiltrate, proliferate or neovascularize may transform the glioma either into a more aggressive tumor at the same grade or elevate its grade.

Entities:  

Keywords:  Angiogenesis; Glioblastoma; Glioma; Mitosis; Motility; Rates; Transformation

Mesh:

Substances:

Year:  2017        PMID: 28451993     DOI: 10.1007/s11060-017-2444-6

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  66 in total

1.  'Go or grow': the key to the emergence of invasion in tumour progression?

Authors:  H Hatzikirou; D Basanta; M Simon; K Schaller; A Deutsch
Journal:  Math Med Biol       Date:  2010-07-07       Impact factor: 1.854

Review 2.  The evolving molecular genetics of low-grade glioma.

Authors:  Sriram Venneti; Jason T Huse
Journal:  Adv Anat Pathol       Date:  2015-03       Impact factor: 3.875

3.  Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells.

Authors:  E G Van Meir; P J Polverini; V R Chazin; H J Su Huang; N de Tribolet; W K Cavenee
Journal:  Nat Genet       Date:  1994-10       Impact factor: 38.330

4.  MIB-1 labeling index in astrocytic tumors--a clinicopathologic study.

Authors:  L Neder; B O Colli; H R Machado; C G Carlotti; A C Santos; L Chimelli
Journal:  Clin Neuropathol       Date:  2004 Nov-Dec       Impact factor: 1.368

5.  A novel pre-clinical in vivo mouse model for malignant brain tumor growth and invasion.

Authors:  Laura M Shelton; Purna Mukherjee; Leanne C Huysentruyt; Ivan Urits; Joshua A Rosenberg; Thomas N Seyfried
Journal:  J Neurooncol       Date:  2010-01-13       Impact factor: 4.130

6.  An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.

Authors:  Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff
Journal:  Science       Date:  2013-04-04       Impact factor: 47.728

7.  Chromosome instability, chromosome transcriptome, and clonal evolution of tumor cell populations.

Authors:  ChongFeng Gao; Kyle Furge; Julie Koeman; Karl Dykema; Yanli Su; Mary Lou Cutler; Adam Werts; Pete Haak; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-15       Impact factor: 11.205

8.  Invasive phenotype observed in 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant sublines of 9L rat glioma cells: a tumor model mimicking a recurrent malignant glioma.

Authors:  Ryuta Saito; John Bringas; Hanna Mirek; Mitchel S Berger; Krys S Bankiewicz
Journal:  J Neurosurg       Date:  2004-11       Impact factor: 5.115

9.  Computational Trials: Unraveling Motility Phenotypes, Progression Patterns, and Treatment Options for Glioblastoma Multiforme.

Authors:  Fabio Raman; Elizabeth Scribner; Olivier Saut; Cornelia Wenger; Thierry Colin; Hassan M Fathallah-Shaykh
Journal:  PLoS One       Date:  2016-01-12       Impact factor: 3.240

10.  IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

Authors:  Heather E Leeper; Alissa A Caron; Paul A Decker; Robert B Jenkins; Daniel H Lachance; Caterina Giannini
Journal:  Oncotarget       Date:  2015-10-06
View more
  2 in total

1.  Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.

Authors:  Hassan M Fathallah-Shaykh; Andrew DeAtkine; Elizabeth Coffee; Elias Khayat; Asim K Bag; Xiaosi Han; Paula Province Warren; Markus Bredel; John Fiveash; James Markert; Nidhal Bouaynaya; Louis B Nabors
Journal:  PLoS Med       Date:  2019-05-28       Impact factor: 11.069

2.  Spatial distribution of malignant transformation in patients with low-grade glioma.

Authors:  Asgeir S Jakola; David Bouget; Ingerid Reinertsen; Anne J Skjulsvik; Lisa Millgård Sagberg; Hans Kristian Bø; Sasha Gulati; Kristin Sjåvik; Ole Solheim
Journal:  J Neurooncol       Date:  2020-01-09       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.